Interní Med. 2013; 15(10): 298-300

Actual possibilities of modern anticoagulant therapy

MUDr.Zdeněk Coufal
Kardiovaskulární centrum, Interní klinika IPVZ, Krajská nemocnice T. Bati, a.s. Zlín

New antikoagulant agents (dabigatran, rivaroxaban and apixaban) give significantly higher possibilities in trombembolic prevention in patients

with nonvaluvular atrial fibrillation with same or higher efficiency and same or lower bleeding risk in comparison with dose adjusted

warfarin. New anticoagulants have advantage especially in pacients with poor warfarin treatment control and/or higher bleeding risk.

Keywords: non-valvular atrial fibrillation, antikoagulant treatment, new antikoagulant agents

Published: October 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Coufal Z. Actual possibilities of modern anticoagulant therapy. Interní Med. 2013;15(10):298-300.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Syzdol M., Tendera M. Stroke prevention in patients with atrial fibrillation - anticoagulation stragegy 2012. Cor et Vasa. 2013, Sv. 55, 128 - 133. Go to original source...
    2. al., Connolly SJ et. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 361, 2009, 1139-1151. Go to original source... Go to PubMed...
    3. al., Connolly Stuart J et. http://circ.ahajournals.org/content/early/2013/06/13/CIRCULATIONAHA.112.001139. [Online]
    4. al., Patel MR et. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011, Sv. 365, 883-891. Go to original source... Go to PubMed...
    5. http://www.escardio.org/about/press/press-releases/esc10-stockholm/Pages/AVERROES-trial.aspx. [Online]
    6. http://www.nejm.org/doi/full/10.1056/NEJMoa1107039.[Online]
    7. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011, Sv. 365, 699-708. Go to original source... Go to PubMed...
    8. al., Mueck W et. Rivaroxaban - Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention. Clin Pharmacokinet. 50 (10), 675-686, 2011. Go to original source... Go to PubMed...
    9. al., Huisman M.V. et. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis 107.5; s. 838-847. 2012. Go to original source... Go to PubMed...
    10. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010, Sv. 376, 975-983. Go to original source... Go to PubMed...
    11. Z., Coufal. Nové možnosti prevence a terapie systémové trombembolie. Interní Med. 2012, Sv. 14, 357-360.
    12. Tendera M., Syzdol M., Parma Z. ARISTOTLE RE-LYs on the ROCKET. What´s new in stroke prevention in patients with atrial fibrillation? Cardiology Journal. 2012, Sv. 19, 4-10. Go to original source... Go to PubMed...
    13. al., Connolly SJ et. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009, Sv. 361, 1139-1151. Go to original source... Go to PubMed...
    14. al., Granger CB et. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011, Sv. 365, 981-992. Go to original source... Go to PubMed...
    15. http://www.nejm.org/doi/full/10.1056/NEJMoa1107039.[Online]
    16. Syzdol M., Tendera M. Stroke prevention in patients with atrial fibrillation - anticoagulation stragegy 2012. Cor et Vasa. 2013, Sv. 55, 128 - 133. Go to original source...
    17. al., Connolly SJ et. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 361, 2009, 1139-1151. Go to original source... Go to PubMed...
    18. al., Connolly Stuart J et. http://circ.ahajournals.org/content/early/2013/06/13/CIRCULATIONAHA.112.001139. [Online]
    19. al., Patel MR et. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011, Sv. 365, 883-891. Go to original source... Go to PubMed...
    20. http://www.escardio.org/about/press/press-releases/esc10-stockholm/Pages/AVERROES-trial.aspx. [Online]
    21. http://www.nejm.org/doi/full/10.1056/NEJMoa1107039.[Online]
    22. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011, Sv. 365, 699-708. Go to original source... Go to PubMed...
    23. al., Mueck W et. Rivaroxaban - Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention. Clin Pharmacokinet. 50 (10), 675-686, 2011. Go to original source... Go to PubMed...
    24. al., Huisman M.V. et. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis 107.5; s. 838-847. 2012. Go to original source... Go to PubMed...
    25. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010, Sv. 376, 975-983. Go to original source... Go to PubMed...
    26. Z., Coufal. Nové možnosti prevence a terapie systémové trombembolie. Interní Med. 2012, Sv. 14, 357-360.
    27. Tendera M., Syzdol M., Parma Z. ARISTOTLE RE-LYs on the ROCKET. What´s new in stroke prevention in patients with atrial fibrillation? Cardiology Journal. 2012, Sv. 19, 4-10. Go to original source... Go to PubMed...
    28. al., Connolly SJ et. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009, Sv. 361, 1139-1151. Go to original source... Go to PubMed...
    29. al., Granger CB et. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011, Sv. 365, 981-992. Go to original source... Go to PubMed...
    30. http://www.nejm.org/doi/full/10.1056/NEJMoa1107039.[Online]

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.